Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases

doi:10.1016/0197-4580(89)90118-8

Neurobiology of Aging

Volume 10, Issue 5, September–October 1989, Pages 515-533

https://doi.org/10.1016/0197-4580(89)90118-8 Get rights and content

Abstract

This review summarizes the current knowledge of characterized neurotrophic factors, including nerve growth factor (NGF) which serves as paradigmatic example when studying novel molecules. Special consideration is given to the function of neurotrophic factors in the adult and aging brain. Strategics are discussed for the eventual development of pharmacological applications of these molecules in the treatment of neurodegenerative diseases.

References (318)

L. Aloe
The effect of nerve growth factor and its antibodies on mast cells in vivo
J. Neuroimmunol.
(1988)
G.R. Auburger et al.
Developmental changes of nerve growth factor and its mRNA in the rat hippocampus: Comparison with choline acetyltransferase
Dev. Biol.
(1987)
A. Baird et al.
Molecular characterization of fibroblast growth factor
F.J. Ballard et al.
Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding
Biochem. Biophys. Res. Commun.
(1987)
Y-A. Barde et al.
Brain-derived neurotrophic factor
Prog. Brain Res.
(1987)
Y.A. Barde et al.
Brain derived neurotrophic factor
(1987)
E.N. Benveniste et al.
Response of human glioblastoma cells to recombinant interleukin-2
J. Neuroimmunol.
(1988)
P. Bernd et al.
Association of 125I-nerve growth factor with PC12 pheochromocytoma cells
N. Bhat
Insulin dependent neurite out growth in cultured embryonic mouse brain cells
Dev. Brain Res.
(1983)
M. Binoux et al.
Production of insulin-like growth factors and their carrier by rat pituitary gland and brain explants in culture
FEBS Lett.
(1981)

B. Bjerre et al.

Short- and long-term effects of nerve growth factor on the sympathetic nervous system in the adult mouse

Brain Res.

(1975)

B. Bjerre et al.

A study of the de- and regenerative changes in the sympathetic nervous system of the adult mouse after treatment with the antiserum to nerve growth factor

Brain Res.

(1975)

N.J. Bohannon et al.

Localization of binding sites for insulin-like growth factor I (IGF-I) in the rat brain by quantitative autoradiography

Brain Res.

(1988)

F.T. Boyd et al.

Insulin inhibits specific norepinephrine uptake in neuronal cultures from rat brain

Brain Res.

(1986)

S.K. Burgess et al.

Characterization of a neuronal subtype of insulin-like growth factor I receptor

J. Biol. Chem.

(1987)

V. Burroughs et al.

Thyroid function in the elderly

Am. J. Med. Sci.

(1982)

P.B.S. Clarke et al.

Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: Neuroanatomical and electrophysiological evidence

Neuroscience

(1987)

D. Collerton

Cholinergic function and intellectual decline in Alzheimer's disease

Neuroscience

(1986)

J. Courty et al.

Presence of basic fibroblast growth factor receptors in bovine brain membranes

J. Biol. Chem.

(1988)

K.A. Crutcher

Sympathetic sprouting in the central nervous system: a model for studies of axonal growth in the mature mammalian brain

Brain Res. Rev.

(1987)

K.A. Crutcher et al.

Sympathetic noradrenergic sprouting in response to central cholinergic denervation

Trends Neurosci.

(1981)

R. Derynck

Transforming growth factor alpha

Cell

(1988)

U. Dohrmann et al.

Muscle-derived factors that support survival and promote fiber outgrowth from embryonic chick spinal motor neurons in culture

Dev. Biol.

(1986)

C.F. Dreyfus et al.

Failure of nerve growth factor to affect fetal mouse brain catecholaminergic neurons in culture

Brain Res.

(1980)

F. Eckenstein

Transient expression of NGF-receptor-like immunoreactivity in postnatal rat brain and spinal cord

Brain Res.

(1988)

D.D. Eveleth et al.

Internalization and cycling of nerve growth factor in PC12 cells: interconversion of type II (fast) and type I (slow) nerve growth factor receptors

Neuron

(1988)

S.P. Finklestein et al.

Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds

Brain Res.

(1988)

F.H. Gage et al.

NGF receptor re-expression and NGF mediated cholinergic neuronal hypertrophy in the damaged adult neostriatum

Neuron

(1989)

F.H. Gage et al.

Experimental approaches to age related cognitive impairments

Neurobiol. Aging

(1988)

F.H. Gage et al.

Grafting genetically modified cells to the brain: possibilities for the future

Neuroscience

(1987)

B.H. Gahwiler et al.

Nerve growth factor is involved in establishment of septo-hippocampal cholinergic projection

Neurosci. Lett.

(1987)

J.W. Geddes et al.

Senile plaques as aberrant sprout-stimulating structures

Exp. Neurol.

(1986)

C. Gensburger et al.

Brain basic fibroblast growth factor stimulates the proliferation of rat neuronal precursor cell in vitro

FEBS Lett.

(1987)

H. Gnahn et al.

NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal forebrain: Evidence for a physiological role of NGF in the brain?

Dev. Brain Res.

(1983)

M. Goedert et al.

Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: Lesion effects in the rat brain and levels in Alzheimer's disease

Mol. Brain Res.

(1986)

M. Goedert et al.

Biochemical effects of antibodies against nerve growth factor on developing and differentiated sympathetic ganglia

Brain Res.

(1978)

F. Gomez-Pinilla et al.

Epidermal growth factor receptor immunoreactivity in rat brain

D. Gospodarowicz et al.

Fibroblast growth factor

Mol. Cell. Endocrinol.

(1986)

D. Gospodarowicz et al.

Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells

Cell Differ. Dev.

(1986)

S.H. Green et al.

A single Mr= 103,000 125I-beta-nerve growth factor-affinity-labeled species represents both the low and high affinity forms of the nerve growth factor receptor

J. Biol. Chem.

(1986)

T. Hagg et al.

Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage

Exp. Neurol.

(1988)

V. Haroutunian et al.

Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor

Brain Res.

(1986)

C.R. Abraham et al.

Immunochemical identification of the serine protease inhibitor alpha-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

Cell

(1988)

J.A. Abraham et al.

Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor

Science

(1988)

J.A. Abrahamn et al.

Human basic fibroblast growth factor: nucleotide sequence and genomic organization

EMBO J.

(1986)

Y. Aizenman et al.

Changes in insulin and transferrin requirements of pure brain neuronal cultures during embryonic development

L. Aloe et al.

Nerve growth factor-induced transformation of immature chromaffin cells in vivo into sympathetic neurons

K.J. Anderson et al.

Basic fibroblast growth factor prevents death of lesioned cholinergic neurons in vivo

Nature

(1988)

S.H. Appel

A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease

Ann. Neurol.

(1981)

C. Ayer-LeLievre et al.

Expression of the beta-nerve growth factor gene in hippocampal neurons

Science

(1988)

Cited by (387)

Cadmium-induced neurotoxic effects on rat basal forebrain cholinergic system through thyroid hormones disruption
2022, Environmental Toxicology and Pharmacology
Cadmium (Cd) single and repeated exposure produces cognitive dysfunctions. Basal forebrain cholinergic neurons (BFCN) regulate cognitive functions. BFCN loss or cholinergic neurotransmission dysfunction leads to cognitive disabilities. Thyroid hormones (THs) maintain BFCN viability and functions, and Cd disrupts their levels. However, Cd-induced BFCN damages and THs disruption involvement was not studied. To research this we treated male Wistar rats intraperitoneally with Cd once (1 mg/kg) or repetitively for 28 days (0.1 mg/kg) with/without triiodothyronine (T3, 40 µg/kg/day). Cd increased thyroid-stimulating-hormone (TSH) and decreased T3 and tetraiodothyronine (T4). Cd altered cholinergic transmission and induced a more pronounced neurodegeneration on BFCN, mediated partially by THs reduction. Additionally, Cd antagonized muscarinic 1 receptor (M1R), overexpressed acetylcholinesterase S variant (AChE-S), downregulated AChE-R, M2R, M3R and M4R, and reduced AChE and choline acetyltransferase activities through THs disruption. These results may assist to discover cadmium mechanisms that induce cognitive disabilities, revealing a new possible therapeutic tool.
Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives
2021, Rheumatic Disease Clinics of North America
Targeting neurotrophic factors: Novel approaches to musculoskeletal pain
2020, Pharmacology and Therapeutics
Chronic pain represents a substantial unmet medical need globally. In recent years, the quest for a new generation of novel, safe, mechanism-based analgesic treatments has focused on neurotrophic factors, a large group of secreted proteins that control the growth and survival of different populations of neurons, but that postnatally are involved in the genesis and maintenance of pain, with biological activity in both the periphery and the central nervous system. In this narrative review, we discuss the two families of neurotrophic proteins that have been extensively studied for their role in pain: first, the neurotrophins, nerve growth factor (NGF) and brain-derived growth factor (BDNF), and secondly, the GDNF family of ligands (GFLs). We provide an overview of the pain pathway, and the pain-producing effects of these different proteins. We summarize accumulating preclinical and clinical findings with a focus on musculoskeletal pain, and on osteoarthritis in particular, because the musculoskeletal system is the most prevalent source of chronic pain and of disability, and clinical testing of these novel agents – often biologics- is most advanced in this area.
Counter effects of Asiaticosids-D through putative neurotransmission on rotenone induced cerebral ganglionic injury in Lumbricus terrestris
2019, IBRO Reports
Asiaticoside-D (AD) was shown to efficacy of ganglionic degenerated Lumbricus terrestris as a pioneering observation in our earlier research. Though, extract molecular mechanisms of AD for degenerative diseases (DDs) remains largely unknown. We investigated the neuroprotective effects of AD against ROT in cerebral ganglions (CGs) of degenerative L. terrestris. Worms were exposed to 0.4 ppm ROT for 7 days were subjected to co- treatment with 15 ppm of AD. After, CGs was removed. The levels oxidant, non-antioxidant, antioxidant status, ganglioside, ceramide and ceramide glycanase (CGase) were estimated. The m-RNA levels of dopamine transporter (DAT), octopamine transporter (OAT), innexins-9 (inx-9), ionotropic glutamate receptor 3 (iGlu3), heat shock proteins (hsp70), XPRLamide neuropeptide precursor, tyramine beta-hydroxylase (tbh-1) and β- adrenergic receptor kinase-2 (β-ARK2–3) by semi-qRT- PCR. The expression pattern of tyramine beta hydroxylase (TBH), glutamate receptor (iGluR), serotonin transporter (SERT), dopamine transporters (DAT), nerve growth factors (NGF), cytochrome C oxidase (COC), NADH dehydogenase subunit-1 (ND-1), neurotrophin receptor p75 (p75NTR), neuronal nitric oxiside synthase (nNOs) interleukin 1- beta (IL1-β) and tumor necrosis factor alpha (TNF-α) by western blotting. Glutaminergic, serotogenic and dopaminergic toxicity variations were also performed. The levels of oxidant, non-antioxidant, antioxidant status, lipids, proteins and m-RNAs were significantly altered (p < 0.001) on ROT-induced (group II) and their levels were significantly changes (p < 0.05) by ROT+AD in CGs. The sensitive study plan concluded the neuroprotective effects of AD against ROT induced degeneration in worms and suggest that the AD deserves future studies for its use as an effective alternative medicine that could minimize the morbidity of ganglionic degenerative diseases patients.
Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease
2017, Biomaterials
Citation Excerpt :
Given their physiological role in activating and modulating neuronal signaling pathways, neurotrophic growth factors represent a very promising, recently explored, disease-modifying biotherapy [2]. Recombinant (r-)platelet-derived growth factor (PDGF), brain-derived neurotrophic factor (BDNF), transforming growth factor (TGF)-β, basic-fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF), administered via intracerebroventricular (ICV) or systemic routes, provide physiological functional benefits in several neurological pathologies, and enhance the survival of dopaminergic neurons in PD cellular and animal models [3,4]. However, recent randomized clinical studies using these single recombinant growth factors drugs did not improve conditions of patients with neurodegenerative conditions [5–7], suggesting that therapeutic approaches combining multiple, complementary neurotrophic growth factors should be evaluated to treat the physiologically complex pathological events associated with PD.
Human platelet lysates (PLs), which contain multiple neurotrophins, have been proposed for treating neurodegenerative disorders, including Parkinson's disease (PD). However, current PLs suspended in plasma have high protein content and contain fibrinogen/fibrin and, following activation, also proteolytic and thrombogenic enzymes. Upon brain administration, such PLs may saturate the cerebrospinal fluid and exert neurotoxicity. We assessed whether purified PLs, concentrated in neurotrophins, protected dopaminergic neurons in PD models. Platelet concentrates were collected by apheresis and centrifuged to eliminate plasma and recover the platelets. Platelets were lysed by freeze-thaw cycles, and the 10-fold concentrated platelet pellet lysates (PPLs) were heat-treated (at 56 °C for 30 min). The heat-treated PPLs were low in total proteins, depleted in both plasma and platelet fibrinogen, and devoid of thrombogenic and proteolytic activities. They exerted very high neuroprotective activity when non-oncogenic, Lund human mesencephalic (LUHMES) cells that had differentiated into dopaminergic neurons were exposed to the MPP⁺ neurotoxin. Heat treatment improved the neuroprotection and inactivated the neurotoxic blood-borne hepatitis C virus. PPL did not induce inflammation in BV2 microglial cells and inhibited COX-2 expression upon lipopolysaccharide exposure. Intranasal administration in mice revealed (a) diffusion of neurotrophins in the striatum and cortex, and (b) MPTP intoxication neuroprotection in the substantia nigra and striatum and the absence of neuroinflammation. These dedicated heat-treated PPLs can be a safe and valuable candidate for a therapeutic strategy for PD.
Prolonged controlled delivery of nerve growth factor using porous silicon nanostructures
2017, Journal of Controlled Release
Although nerve growth factor (NGF) is beneficial for the treatment of numerous neurological and non-neurological diseases, its therapeutic administration represents a significant challenge, due to the difficulty to locally deliver relevant doses in a safe and non-invasive manner. In this work, we employ degradable nanostructured porous silicon (PSi) films as carriers for NGF, allowing its continuous and prolonged release, while retaining its bioactivity. The PSi carriers exhibit high loading efficacy (up to 90%) of NGF and a continuous release, with no burst, over a period of > 26 days. The released NGF bioactivity is compared to that of free NGF in both PC12 cells and dissociated dorsal root ganglion (DRG) neurons. We show that the NGF has retained its bioactivity and induces neurite outgrowth and profound differentiation (of > 50% for PC12 cells) throughout the period of release within a single administration. Thus, this proof-of-concept study demonstrates the immense therapeutic potential of these tunable carriers as long-term implants of NGF reservoirs and paves the way for new localized treatment strategies of neurodegenerative diseases.

View all citing articles on Scopus

View full text

ReviewFunction of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases

Abstract

J. Neuroimmunol.

Dev. Biol.

Biochem. Biophys. Res. Commun.

Prog. Brain Res.

Brain derived neurotrophic factor

J. Neuroimmunol.

Dev. Brain Res.

FEBS Lett.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

J. Biol. Chem.

Am. J. Med. Sci.

Neuroscience

Neuroscience

J. Biol. Chem.

Brain Res. Rev.

Trends Neurosci.

Cell

Dev. Biol.

Brain Res.

Brain Res.

Neuron

Brain Res.

Neuron

Neurobiol. Aging

Neuroscience

Neurosci. Lett.

Exp. Neurol.

FEBS Lett.

Dev. Brain Res.

Mol. Brain Res.

Brain Res.

Mol. Cell. Endocrinol.

Cell Differ. Dev.

J. Biol. Chem.

Exp. Neurol.

Brain Res.

Immunochemical identification of the serine protease inhibitor alpha-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease

Cell

Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor

Science

Human basic fibroblast growth factor: nucleotide sequence and genomic organization

EMBO J.

Changes in insulin and transferrin requirements of pure brain neuronal cultures during embryonic development

Nerve growth factor-induced transformation of immature chromaffin cells in vivo into sympathetic neurons

Basic fibroblast growth factor prevents death of lesioned cholinergic neurons in vivo

Nature

A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease

Ann. Neurol.

Expression of the beta-nerve growth factor gene in hippocampal neurons

Science

Review
Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases